INDICATIONS
AND USES
Celontin is indicated for the control of absence (petit
mal) seizures that are refractory to other drugs.
DOSAGE AND ADMINISTRATION
Optimum dosage of Celontin must be determined by trial.
A suggested dosage schedule is 300 mg per day for the
first week. If required, dosage may be increased thereafter
at weekly intervals by 300 mg per day for the three weeks
following to a daily dosage of 1.2 g. Because therapeutic
effect and tolerance vary among patients, therapy with
Celontin must be individualized according to the response
of each patient. Optimal dosage is that amount of Celontin
which is barely sufficient to control seizures so that
side effects may be kept to a minimum. The smaller capsule
(150 mg) facilitates administration to small children.
Celontin may be administered in combination with other anticonvulsants
when other forms of epilepsy coexist with absence (petit
mal).
HOW SUPPLIED
N 0071-0525-24 (P-D 525) Celontin capsules, #1 capsule
each containing 300 mg methsuximide; bottles of 100.
N 0071-0537-24 (P-D 537) Celontin capsules, Half Strength,
#3 capsule each containing 150 mg methsuximide, bottles
of 100.
Store at 25°C (77°F); excursions permitted to
15-30°C (59-86°F) [see USP Controlled Room Temperature].
Protect from light and moisture.
Protect from excessive heat 40°C (104°F).
Rx only
©1997-'00, Warner-Lambert Co.
PARKE-DAVIS
Div. of Warner-Lambert Co
Morris Plains, NJ 07950 USA
MADE IN FRANCE
|
|
